|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> CXCL14 protein was expressed in the cytoplasm adjacent to tumors.
|
28928893 |
2017 |
|
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>TP53</i>WT endometrioid OC highly expressed CXCL14 compared to <i>TP53</i>m, showing better progression-free survival but no difference in overall survival (OS).
|
30181917 |
2018 |
|
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>TP53</i>WT endometrioid OC highly expressed CXCL14 compared to <i>TP53</i>m, showing better progression-free survival but no difference in overall survival (OS).
|
30181917 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>TP53</i>WT endometrioid OC highly expressed CXCL14 compared to <i>TP53</i>m, showing better progression-free survival but no difference in overall survival (OS).
|
30181917 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour panel blots showed that BRAK was down-regulated in cervical adenocarcinoma and uterine leiomyoma, but was up-regulated in breast invasive ductal carcinoma.
|
10784614 |
2000 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer-associated fibroblast-derived CXCL14 enhances tumour growth in mouse models of prostate and breast cancer.
|
27115465 |
2016 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer-associated fibroblast-derived CXCL14 enhances tumour growth in mouse models of prostate and breast cancer.
|
27115465 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CXCL14 RNA expression was observed in normal and tumor prostate epithelium and focally in stromal cells adjacent to cancer.
|
15651028 |
2005 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CXCL14 RNA expression was observed in normal and tumor prostate epithelium and focally in stromal cells adjacent to cancer.
|
15651028 |
2005 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CXCL14 mRNA upregulation is a common feature in prostate cancer.
|
15651028 |
2005 |
|
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CXCL14 mRNA upregulation is a common feature in prostate cancer.
|
15651028 |
2005 |
|
Prostatic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.
|
19218429 |
2009 |
|
Squamous cell carcinoma of the head and neck
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
BRAK/CXCL14 (breast- and kidney-expressed chemokine/CXC chemokine ligand 14) is a chemokine that is expressed in many normal cells and tissues but is absent from or expressed at very low levels in transformed cells and cancerous tissues, including HNSCC (head and neck squamous cell carcinoma).
|
20067447 |
2010 |
|
Epithelioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CXCL14 expression is constitutive in normal tissues, but absent in wide range of epithelial tumors.
|
21556757 |
2012 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CXCL14 protein level is positively correlated to the overall survival of all patients as well as the patients with lymph node metastasis, and it has a negative correlation with the lymph node metastasis.
|
22910931 |
2012 |
|
Malignant neoplasm of breast
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
CXCL14 mRNA expression is lower in breast cancer cell lines, and MDA-MB-231HM express the lowest levels of CXCL14 mRNA.
|
22910931 |
2012 |
|
Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
CXCL14 mRNA expression is lower in breast cancer cell lines, and MDA-MB-231HM express the lowest levels of CXCL14 mRNA.
|
22910931 |
2012 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
CXCL14, a recently described epithelial cytokine, plays putative multiple roles in inflammation and carcinogenesis.
|
23597004 |
2013 |
|
Colorectal Carcinoma
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
CXCL14 was methylated in 79.4% (85/107) of primary human colorectal cancer.
|
24099668 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
CXCL14 was methylated in 79.4% (85/107) of primary human colorectal cancer.
|
24099668 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CXCL14 is a member of the CXCL chemokine family and exhibits various expression patterns in different types of tumor, even those tumors that occur in the same type of tissue.
|
24938992 |
2014 |
|
Secondary Neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.
|
26428435 |
2015 |
|
Carcinoma, Endometrioid
|
0.010 |
Biomarker
|
disease |
BEFREE |
CXCL14-CXCR4 and CXCL12-CXCR4 Axes May Play Important Roles in the Unique Invasion Process of Endometrioid Carcinoma With MELF-Pattern Myoinvasion.
|
28277316 |
2017 |
|
HIV-1 infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
CXCL14 did not activate CXCR4-expressing cells (<i>i.e.,</i> failed to trigger chemotaxis and Ca<sup>2+</sup> mobilization, as well as signaling <i>via</i> ERK1/2 and the small GTPase Rac1); however, CXCL14 bound to CXCR4 with high affinity, induced redistribution of cell-surface CXCR4, and enhanced HIV-1 infection by >3-fold.
|
28360196 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CXCL14 is a primordial chemokine that plays multiple roles in tumor suppression, autoimmune arthritis, and obesity-associated insulin resistance.
|
28928016 |
2017 |